Biblio
Found 14 results
Filters: Keyword is Ligands [Clear All Filters]
Biphalin: The Foundation of Bivalent Ligands.. Curr Med Chem. 23(29):3267-3284.
.
2016. Cyclic non-opioid dynorphin A analogues for the bradykinin receptors.. Bioorg Med Chem Lett. 26(22):5513-5516.
.
2016. Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.. Bioorg Med Chem Lett. 26(1):222-7.
.
2016. Various modifications of the amphipathic dynorphin A pharmacophore for rat brain bradykinin receptors.. Chem Biol Drug Des. 88(4):615-9.
.
2016. Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.. Bioorg Med Chem Lett. 25(20):4683-8.
.
2015. Design, synthesis, and biological evaluation of a series of bifunctional ligands of opioids/SSRIs.. Bioorg Med Chem. 23(6):1251-9.
.
2015. .
2015. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.
.
2014. Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor.. Bioorg Med Chem. 22(22):6360-5.
.
2014. Development of functionally selective, small molecule agonists at kappa opioid receptors.. J Biol Chem. 288(51):36703-16.
.
2013. Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.. Bioorg Med Chem Lett. 23(17):4975-8.
.
2013. Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.
.
2011. Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.
.
2011. Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.
.
2010.